SGLT2 inhibition reduces myocardial oxygen consumption

SGLT2 inhibition reduces myocardial oxygen consumption

Aims/hypothesis: SGLT2 inhibition is associated with a reduced risk of cardiac disease that is still largely unexplained. According to one hypothesis, improved myocardial energetics may explain the cardioprotective effects of SGLT2i. However, recent mechanistic studies that have addressed this quest...

Full description

Bibliographic Details
Main Authors:	Esben Søndergaard, Esben S. Lauritzen, Katrine M. Lauritsen, Axel Åkerblom, Pirjo Nuutila, Jonas Oldgren, Lars C. Gormsen
Format:	Article
Language:	English
Published:	Elsevier 2022-09-01
Series:	Metabolism Open
Subjects:	Myocardial external efficiency Myocardial oxygen consumption SGLT2 inhibitors Type 2 diabetes Meta-analysis
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589936822000457

Similar Items

SGLT2 Inhibition in Acute Myocardial Infarction—A Comprehensive Review
by: Martin Benedikt, et al.
Published: (2023-01-01)

Effects of SGLT2 inhibition on lipid transport in adipose tissue in type 2 diabetes
by: Katrine M Lauritsen, et al.
Published: (2022-04-01)

Timing of SGLT2i initiation after acute myocardial infarction
by: Dirk von Lewinski, et al.
Published: (2023-09-01)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
by: Alex Ali Sayour, et al.
Published: (2021-09-01)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
by: Chenguang Li, et al.
Published: (2019-02-01)

SGLT-2 inhibitors: Post infarction interventional effects
by: Pugazhenthan Thangaraju, et al.
Published: (2023-03-01)

Association of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Use With Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients With Stabilized Acute Myocardial Infarction: A Propensity Score Matching Study
by: Ting-Yung Chang, et al.
Published: (2022-04-01)

Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry
by: Pasquale Paolisso, et al.
Published: (2022-05-01)

Sotagliflozin attenuates cardiac dysfunction and remodeling in myocardial infarction rats
by: Peng Zhong, et al.
Published: (2023-11-01)

Myocardial Oxygen Consumption and Efficiency in Aortic Valve Stenosis Patients With and Without Heart Failure
by: Nils Henrik Stubkjær Hansson, et al.
Published: (2017-02-01)

In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study
by: Arturo Cesaro, et al.
Published: (2022-09-01)

Novel cardioprotective mechanism for Empagliflozin in nondiabetic myocardial infarction with acute hyperglycemia
by: Ruhua Deng, et al.
Published: (2022-10-01)

Editorial: Clinical prospective of SGLT2 inhibitors in atherosclerosis
by: Annalisa Capuano, et al.
Published: (2022-11-01)

Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report
by: Lucia Leccisotti, et al.
Published: (2022-09-01)

Effects of the SGLT2 Inhibition on Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats, a Model of Type 1 Diabetes Mellitus
by: Camila Moreno Rosa, et al.
Published: (2022-05-01)

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
by: Lucia Scisciola, et al.
Published: (2023-02-01)

GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes
by: Raffaele Marfella, et al.
Published: (2024-01-01)

Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
by: Lixin Du, et al.
Published: (2022-11-01)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
by: Liu S, et al.
Published: (2019-07-01)

SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis
by: Qing Zhang, et al.
Published: (2024-01-01)

The influence of dapagliflozin on cardiac remodeling, myocardial function and metabolomics in type 1 diabetes mellitus rats
by: Eder Anderson Rodrigues, et al.
Published: (2023-10-01)

Cardioprotective Effects of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension Are Mediated by the Local Reduction of Sympathetic Activity and Inflammation
by: Giovanna Castoldi, et al.
Published: (2023-06-01)

Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials
by: Lucia Scisciola, et al.
Published: (2022-09-01)

Safety of SGLT2 inhibitors in very elderly diabetic type 2 patients in real life
by: Ramón Baeza-Trinidad, et al.
Published: (2023-07-01)

Adrenal SGLT1 or SGLT2 as predictors of atherosclerosis under chronic stress based on a computer algorithm
by: Jianyi Li, et al.
Published: (2023-08-01)

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
by: Jennifer Matthews, et al.
Published: (2023-09-01)

Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial
by: Mikkel Jürgens, et al.
Published: (2021-08-01)

The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition
by: Muhammad Saad, et al.
Published: (2018-11-01)

Toxicological assessment of SGLT2 inhibitors metabolites using in silico approach
by: JÉSSICA B. DE JESUS, et al.
Published: (2022-10-01)

SGLT2-inhibitors are effective and safe in the elderly: The SOLD study
by: Maria Elena Lunati, et al.
Published: (2022-09-01)

The Effect Of SGLT-2 Inhibitors On Improving Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
by: Wasef Sayeh, et al.
Published: (2023-12-01)

Three Levels of Disease Modification with SGLT-2 Inhibitors: Holy Grail in Vasculopathy
by: Archit Dhaiya; Rajeev Sharma; Nagendra Bhoopathy; Rajeev Agarwal
Published: (2023-07-01)

Myocardial Oxygen Consumption and Efficiency in Patients With Cardiac Amyloidosis
by: Tor Skibsted Clemmensen, et al.
Published: (2018-11-01)

SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy
by: Dominique Croteau, et al.
Published: (2023-04-01)

A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present
by: Jonali Ramani, et al.
Published: (2022-12-01)

External Validation and Extension of a Clinical Score for the Discrimination of Type 2 Myocardial Infarction
by: Thomas Nestelberger, et al.
Published: (2021-03-01)

Ketone Body Infusion With 3‐Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study
by: Lars C. Gormsen, et al.
Published: (2017-03-01)

A Fluorescent Glucose Transport Assay for Screening SGLT2 Inhibitors in Endogenous SGLT2-Expressing HK-2 Cells
by: Yan-Ting Lu, et al.
Published: (2018-11-01)

SGLT-2 Inhibitors: Are They a Promising Treatment Option in T2DM Patients with NAFLD?
by: Dimitrios Patoulias
Published: (2018-04-01)

SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
by: Swetha R. Kanduri, et al.
Published: (2020-08-01)